Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Lonza expands early-development services with new Cambridge lab

By Brian Buntz | February 13, 2023

LonzaCDMO giant Lonza Group (OTCMKTS:LZAGY) has revealed its plans to establish a new lab in Cambridge, Massachusetts. The facility will primarily support small- and medium-sized biotech companies. In particular, the facility will help clients optimize candidates by detecting and resolving potential issues in the early-stages of development before starting clinical trials.

This move is part of Lonza’s wider strategy to expand its presence in Europe and North America.

The new Cambridge lab, slated to become operational in May 2023, will mark the expansion of Lonza’s Early Development Services (EDS) into the North American market.

Lonza’s EDS initiative provides a complete range of in silico and in vitro early stage services to help pharmaceutical and biotech firms minimize risks and optimize their selection of late-stage candidates and lead candidate development. Additionally, EDS offers early, phase-specific non-GMP protein expression through the company’s Light Path Discovery platform.

Approximately one out of 1,000 molecules succeeds beyond Phase 1 studies, noted Jean-Christophe Hyvert, the President of Biologics at Lonza. “In this environment, early development services are essential in mitigating risks, reducing attrition and improving the quality and safety of biologic treatments,” he said in a press release.

Lonza also finished expanding its small molecule production facility located in Bend, Oregon in 2023 as part of their efforts to improve their solid form services.

Also last year, the company, based in Basel, Switzerland, announced plans to expand its drug product manufacturing services in its home country. Then, the company announced that it would be adding a new aseptic fill and finish line in Stein, Switzerland. This new line will allow the company to manufacture various types of drugs, including monoclonal antibodies, bioconjugates and viral vectors. The expansion is expected to be completed this year.

Last year, Lonza also bolstered its drug product services in the vicinity of Basel. Specifically, its investment in the Stücki Technologiepark will enhance its offerings for both early- and late-stage clinical trials. This expansion will also boost its abilities in the areas of integrated drug substances and drug products. The company intends to complete this expansion by 2024.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE